[36 Pa.B. 4277]
[Saturday, August 5, 2006]
[Continued from previous Web Page] PACE Provider Bulletins: 1997
* 02/07/97: Brand Medically Necessary Update: Notified Providers that effective immediately PACE is no longer mandating generic reimbursement on the following brand medications: Lasix, Depakene, Tegretol, Mysoline, Quinaglute Duratabs (Quinidine Gluconate), Pronestyl SR, Mexitil, and All Sustained Release Theophylline Preparations.
* 02/14/97: Mandatory Substitution Nitoglycerin Transdermal Patch: Notified Providers that effective February 21, 1997, the PACE Program will being mandating substitution on both Nitro-Dur and Transderm-Nitro.
* 03/01/97: PACENET: Reminder to Providers to encourage their older customers to make application for the new PACENET Program. Bulletin includes income requirements, information regarding the crediting of out-of-pocket expenses; use of 1997 PACE applications to apply for both PACE and PACENET and a reminder to discard the old 1996 enrollment applications.
* 03/28/97: Drug Utilization Review Program: Notified Providers that effective April 14, 1997, PACE will be adding new criteria to our Prospective Drug Utilization Review Program for HMG Co-A Reductase Inhibitors.
* 05/09/97: PACENET Claim Submission: Provides explanation to Providers regarding the $500 deductible and submission of out-of-pocket prescription expenses for PACENET cardholders.
* 06/20/97: Claim Timeliness: Reminder to Providers that PACE claims are to be submitted on the date of dispensing.
* 07/11/97: Fragmin: Notified Providers that on July 18, 1997, PACE would reimburse claims submitted for Fragmin only when being prescribed for the prevention of deep venous thrombosis, which may lead to a pulmonary embolism following abdominal surgery or hip replacement. Further, since Fragmin is indicated for short-term treatment (five to ten days), PACE would apply a duration of therapy edit of not greater than 14 days to all incoming claims.
* 8/7/97: Generic Update: Ranitidine: Notified Providers that Ranitidine currently being manufactured by Novopharm and Geneva is now available as a therapeutically equivalent generic for Zantac and effective Friday, August 15, 1997, PACE would be mandating substitution on Ranitidine.
* 8/7/97: 1997 Pharmacy Licensure: Reminder to Pharmacies that current pharmacy licenses expire August 31, 1997 and that PACE Regulations mandate that, ''Only pharmacies and dispensing physicians that are currently licensed by the Commonwealth are eligible to participate as providers in the PACE Program.''
* 8/15/97: PACENET Claims: Reminder to Providers that they must submit all PACENET Cardholder prescription claims on POCAS to permit the accurate recording of the amount accumulating toward the $500 deductible.
* 8/15/97: Other Prescription Coverage: Reminder to Providers that, by statute, the PACE Program is the payor of last resort and will accept responsibility only for those costs not covered by the cardholder's other prescription drug benefit program.
* 8/15/97: Notified Providers effective August 18, 1997, several new maximum dose criteria will be added to the PACE ProDUR Program. These new additions are: 1) Maximum daily dose and duplicate therapy (with ACE inhibitors) edit for angiotensin II antagonist inhibitor: Valsartan (Diovan) 320 mg; 2) Maximum initial dose and maximum daily dose for antipsychotic agent Olanzapine (Zyprexa) 2.5 mg (initial) 10 mg (maximum); 3) Maximum daily dose and duplicate therapy for the HMG Co-A Reductase Inhibitor: Atorvastatin (Lipitor) 80 mg (maximum); 4) Maximum daily dose and duplicate therapy for the beta blocker: Cavedilol (Coreg) 100 mg (maximum); 5) Maximum initial dose and maximum daily dose for the antidepressant: Mirtazapine (Remeron) 15 mg (initial) 45 (maximum); 6) Maximum dose and duplicate therapy for the calcium channel blocker Nisoldipine (Sular) 60 mg (maximum); and 7) Maximum initial dose and maximum daily dose for the antipsychotic: Clozapine (Clozaril) 25 mg (initial) 100 mg (maximum).
* 8/29/97: Updated listing of Nonparticipating Manufacturers.
* 9/12/97: Reinstatement of Common Package Size: Notified Providers effective September 15, 1997, PACE will reinstitute the Common Package Size pricing which was discontinued in November, 1996.
* 9/19/97: Audit Issues: Reminder to Providers their responsibilities regarding voiding claims' payments for prescriptions that are not picked up by cardholders as well as maintaining an accurate, current signature log to identify the individuals who are receiving the PACE prescriptions dispensed by the Provider.
* 9/19/97: DAW/Product Selection Code: Reminder to Providers of the five codes used by POCAS.
* 10/3/97: Injectable Chemotherapy Antineoplastics: Reminder to Providers that Injectable chemotherapeutic antineoplasic claims are only reimbursed based on the 20% not covered by Medicare.
* 10/3/97: Claim Submission Timeliness: Reminder to Providers that they are required by contract to submit claims prior to dispensing.
* 10/17/97: Other Prescription Coverage: Notification to Providers effective November 3, 1997, PACE is implementing edit criteria to ensure compliance with the Program's requirement of billing other prescription plans prior to billing PACE. Providers entering a TPL indicator identifying ''no other coverage'' for a cardholder identified as having other prescription coverage will have the claim denied with the NCPDP Error Code 41 ''Submit Bill to Other Payor.''
* 11/14/97: Drug Utilization Review Program: Notified Providers effective November 24, 1997, the following new maximum daily dose criteria will be added to the PACE ProDUR Program: Maximum daily dose edit for the centrally acting analgesic Tramadol (Ultram) 300 mg maximum for individuals 75 years of age or older and 400 mg for individuals younger than 75 years.
* 11/14/97: Drug Utilization Review Program: Notified Providers effective November 24, 1997, the following new maximum daily dose criteria will be added to the PACE ProDUR Program: Edits for the miscellaneous sedative/hypnotics are as follows: Amobarbital (Amytal) 200 mg; Butabarbital (Butisol) 100 mg; Chloral Hydrate 1 gm; Pentobarbital (Nembutal) 100 mg; Ethchlorvynol (Placidyl) 500 mg; Secobarbital (Seconal) 100 mg; Amobarbital/Secobarbital (Tuinal) 50/50 mg.
* 11/21/97: Reminder to PACE Providers to review their Remittance Advice and to pay particular attention to those claims with Message Codes 041 and 918, which address those claims for cardholders with other prescription coverage.
* 11/21/97: Oral Anti-Nausea Medication: Notified Providers effective December 1, 1997, PACE will being reimbursing only 20% of the Average Wholesale Price of oral formulations of Kytril and Zofran. Remaining cost of the drug will have to be submitted to the regional Medicare carrier, United Health Care in Wilkes-Barre for reimbursement.
* 12/26/97: Reminder to PACE Providers that claims submitted for brand name pharmaceuticals having an A-rated generic therapeutic equivalent will be denied unless a medical exception is granted or PACE does not mandate substitution for the product. PACE does not require substitution on these products with A-rated generics Warfarin Sodium (Coumadin); Carbamazepine (Tegretol); Phenytoin (Dilantin); or Furosemide (Lasix).
PACE Provider Bulletins: 1996
* 1/08/96: Prilosec and Prevacid: Notified Providers these drugs would be edited for maximum duration for all claims dispensed on or after January 8, 1996.
* 1/26/96: Nonparticipating Manufacturer List.
* 5/24/96: Biaxin Filmtabs (NDC: 00074248660): Notified providers of an error on the formulary file from 1/22/96 to 3/21/96.
* 5/24/96: Solopak Pharmaceuticals: Notified providers that Labeler Codes 39769 and 59747 would be participating in the PACE Program.
* 7/12/96: PACE Cardholders with PEBTF Prescription Coverage: Notified Providers that PACE Cardholders with drug coverage through the Commonwealth's Retired Employees Health Plan had been notified they were being canceled from the PACE Program.
* 8/2/96: Other Insurance Coverage: Reminder to Providers to exercise reasonable diligence in ascertaining the existence of other prescription benefits before billing the PACE Program.
* 10/18/96: Injectable Chemotherapeutics: Reimbursement restrictions (20% of Average Wholesale Price) applied to injectable chemotherapy medications when administered through a home infusion pump or in a physician's office.
* 10/18/96: Vaccine Reimbursement: Notified Providers of a change in the reimbursement of vaccines to be implemented on November 11, 1996 for claims with a date-of-service on or after that date. The change is as follows: Vaccines used to provide immunization against pneumococcal pneumonia and influenza will no longer be reimbursed by the PACE Program. Vaccines used to provide immunization against hepatitis B will be reimbursed at 20% of the Average Wholesale Price.
* 10/18/96: Bronchodilator Drugs: Notified Providers that effective November 11, 1996, PACE will begin reimbursing only 20% of Average Wholesale Price for the following products: Acetylcysteine 10%; Acetylcysteine 20%; Albuterol Sulfate 0.083%; Albuterol Sulfate 0.5%; Cromolyn Sodium; Isoetharine HCI 0.1%; Isoetharine HCI 0.125%; Isoetharine HCI 0.167%; Isoetharine HCI 0.2%; Isoetharine HCI 0.25%; Isoetharine HCI 1.0%; Isoproternol HCI 0.5%; Isoproternol HCI 1.0%; Metaproternol Sulfate 0.4%; Metaproterenol Sulfate 0.6%; and Metaproterenol Sulfate 5.0%.
* 11/21/96: PACE Legislative Changes: Notified Providers of increased income limits ($14,000 maximum for singles and $17,200 maximum for married); and Mandatory Substitution of A-Rated Multiple-source products.
* 11/21/96: PACENET Requirements: Notified Providers of income limits for PACENET cardholders (Between $14,000 and $16,000 if single; Between $17,200 and $19,200 if married); Annual Deductible ($500 per person) which PACE Providers are expected to enter PACENET Enrollee's out-of-pocket prescription expenses in POCAS; Mandatory Copayments ($8 per prescription for non-innovator, multiple-source (generic) products; and $15 per prescription for single-source and innovator multiple-source products); Mandatory Substitution of A-Rated Multiple-source products after deductible is met; and the claims reimbursement formula for PACENET claims would be AWP - 10% + $3.50 dispensing fee.
* 11/22/96: Third Party Liability: Notified Providers that a PACE cardholder's I.D. card could currently contain two indicators that may affect coverage. The first indicator is a ''Y'' appearing in the lower right quadrant of the I.D. card meaning the cardholder has informed PACE that they have other third party insurance that is to be billed before PACE. The second indicator is an ''L'' appearing in the lower right quadrant of the I.D. card. This ''L'' means the cardholder has been restricted into receiving their PACE benefits at one specific provider.
* 11/22/96: Lovenox: Notified Providers that effective December 9, 1996, PACE will reimburse claims submitted for Lovenox only when being prescribed for the prevention of deep venous thrombosis, which may lead to a pulmonary embolism following hip or knee replacement surgery or general surgery which includes abdominal, gynecologic, urologic or thoracic. Further, since Lovenox is indicated for short-term treatment (seven to ten days), the Program will apply a duration edit of not greater than 14 days to all incoming claims.
* 11/22/96: Oral Vancomycin: Notified Providers that PACE would be applying a duration of therapy edit of not greater than 14 days for all incoming claims for oral Vancomycin.
* 11/22/96: Bronchodilator Drug Update: Reminder for Providers that reimbursement for the bronchodilator solutions used in either IPPB machines or nebulizers is limited to 20% of the Average Wholesale Price by PACE and suggested that Providers who do not currently have a Medicare provider number contact the National Supplier Clearinghouse in North Carolina to request an application.
* 11/22/96: Nonparticipating Manufacturers effective November 27, 1996.
* 12/01/96: Processing PACENET Claims: Provides information to assist pharmacies in the processing of claims for cardholders enrolled in PACENET.
* 12/13/96: Imitrex Tablets: Notified Providers that effective December 30, 1996, all claims for Imitrex will not be reimbursed for a quantity greater than nine or a days' supply less than or equal to 25.
* 12/13/96: Nimotop: Notified Providers that effective December 30, 1996, claims for Nimotop will be denied at the point-of-sale. After determining the diagnosis, providers can contact the POCAS operators and obtain a Medical Exception. Although this medication is approved only for use in subarachnoid hemorrhage, there are several other off-label uses for which reimbursement will be made.
* 12/13/96: Revision: Nonparticipating Manufacturer List.
* 12/20/96: Mandatory Generic Substitution: Advises providers to direct cardholder questions about the new mandatory substitution policy to the Cardholder Services toll-free number (1-800-225-7223)
PACE Provider Bulletins: 1995
--1/6/95: Drug Utilization Review Program: Addition of new criteria for antidepressants, antipsychotics and benzodiazepines.
--2/17/95: Antidepressants, Antipsychotics and Benezodiazepines: Reminder to Pharmacy to carefully review both the reject codes and accompanying messages.
--2/24/95: Toradol: Reimbursement restrictions.
--2/24/95: Minitran: 30-day supply limit.
--3/95: PACE Drug Utilization Review Criteria.
--3/3/95: Medicare Update: Extended coverage for prescription drugs used in immunosuppressive therapy to three years following hospital discharge for an organ transplant.
--3/3/95: Maximum Initial Dose for selected antipsychotic, antidepressant or benezodiazepine agents.
--3/27/95: Nonsedating Antihistamines and Oral Antifungals Coadministration is Contraindicated. PACE will reject claims for Seldane, Seldane-D, Hismanal, Claritin, Claritin-D, Diflucan, Nizoral and Sporanox.
--3/95: Third Party Billing Reminder: PACE is payer of last resort, pharmacy must bill other third parties first.
--5/5/95: Brand Patent Expirations/Generic Substitutions.
--7/95: CellCept Billing Instructions.
--7/1/95: Claims Submissions: 90-day limit to file claims for reimbursement.
--8/1/95: Injectable Chemotherapeutics: Effective 9/1/95 PACE Reimbursement for list of injectable chemotherapeutics limited to 20% of AWP.
--8/18/95: Nonparticipating Manufacturer List.
--8/18/95: Drug Utilization Review Program: New maximum dose criteria added to the PACE ProDur Program effective 8/28/95--Nefazodone (Serzone) 600 mg/day; Fluvoxamine (Luvox) 50 mg/day (initial) and 300 mg/day (maximum); Lansoprazole (Prevacid) 30 mg/day.
--9/1/95: Common Package Size Reimbursement Listing.
--9/1/95: Epoetin Alfa (EPO) Injections: Effective 9/11/95 PACE reimbursing only 20% of AWP for Epogen and Procrit.
--9/6/95: Early Refill Edit: Additional classes added to the Early Refill Edit.
--9/22/95: Drug Utilization Review Program: Effective 9/25/95 duplicate therapy edit applied to the following class of drugs: Proton Pump Inhibitors--Prilosec and Prevacid.
--10/95: PACE POCAS Telecommunications Number: New direct number available to pharmacy providers for Primary Claim Submission: 950-5545.
PACE Provider Bulletins: 1994
--2/8/94: Reimbursement Criteria for Temazepam (effective 3/1/94).
--5/23/94: Glyburide: Mandatory Substitution of Micronase and Diabeta.
--5/94: Prograf Billing Instructions
--5/94: Ophthalmics: Days Supply Provisions
--5/94: Betaseron Billing Instructions
--7/1/94 Ophthalmics: Noted billing discrepancies regarding pharmacies reporting of the days supply.
--7/23/94: Narrow Therapeutic Index Exemption Listing (Revised)
--8/94: Incorrect Physician License Numbers: Notice to Pharmacy Providers of Procedures to Disallow Claims Submitted with Wrong Prescriber I.D.
--8/19/94: Physician/Medical Assistants: PACE Reimbursement of Prescriptions Written by Physician Assistants.
--9/23/94: Serevent: PACE will no longer reimburse for more than 13 gm of Serevent per prescription.
--9/26/94: Febatol--No PACE Reimbursement after 12/26/94.
--9/30/94: Manufacturers' Rebate Update
--10/3/94: DAW/Product Selection Code (Revised)
--10/21/94: Oral Contraceptives: Effective 10/30/94 PACE no longer reimburses except through the Medical Exception process.
--10/21/94: New Maximum Dose Criteria Added to the PACE ProDUR Program: Maximum daily dose and duplicate therapy criteria for NSAIDs (Trilisate; Disalcid; and Cataflam) and maximum daily dose criteria for miscellaneous anti-ulcer preparations (Propulsid and Reglan).
--11/18/94: Oral Chemotherapeutics: Effective 12/15/94 PACE reimburses only 20% of AWP for Cyclophosphamide 25 mg/oral; Cytoxan 50 mg/oral; Etoposide/Vepesid 50 mg/oral; and Melphalan/Alkeran 2 mg/oral.
--12/2/94: 30-Day Supply Requirement: Humulin and Solganal.
PACE Provider Bulletins: 1993
--1/1/93: PACE Legislative Changes Effective 1/1/93
* Dispense as Written (DAW) Codes
* Mandatory Generic Substitution when an ''A'' rated generic therapeutically equivalent drug is available.
* Pricing Information
* Consultation Fee Discontinued
--2/28/93: Deadline for PACE Provider Reenrollment and Conversion to 3.2 NCPDP
Telecommunications Standard for PACE.
Telecommunications Standard for Claims Submission.
--3/1/93: Standard Error Codes
--3/1/93: Early Refill Edit
--3/1/93: Halcion Error Code Revisions
--3/1/93: Processing Requirements: Conversion to NCPDP Version 3.2
--3/19/93: POCAS System Maintenance on 4/10/93 and 4/11/93.
--5/14/93: Delay in Provider Reimbursement
--5/21/93: Change in the ProDUR screening criteria for H2 Receptor Antagonists effective 6/1/93.
--6/28/93: Implementation of PACE ProDUR Changes:
* Maximum daily dose for NSAIDs
* Maximum daily dose for Omeprazole, Sucralfate and Misoprostrol.
* Maximum daily dosage allowed for Famotidine (Pepcid) changed from 80 mg/day to 40 mg/day.
--6/28/93: Claims Processing Procedures When POCAS Is Not Available.
--7/1/93: Nonparticipating Manufacturers List
--7/23/93: 30-Day Supply Requirements
--7/23/93: Narrow Therapeutic Index Exemption Listing (Revised)
--9/28/93: Manufacturers Rebate Update (Nonparticipating Manufacturer List, effective 10/5/93 was attached.)
PACE Provider Bulletins: 1992
--4/92: Provider Training Seminars (5/11/92 through 7/2/92)
--5/29/92: Manufacturers' Rebate News: Center Laboratories
--6/19/92: Manufacturers' Rebate News: Roxane Laboratories, Inc.
--Astra Pharmaceutical Products
--Ocumed
--IPR Pharmaceutical
--Immunex Corporation
--8/16/92: PACE Rescue Plan: Implementation of ProDUR; NCPDP Version 3.2 and related Program Changes
--9/92: Dixon-Shane recoupments/pharmacy credits.
--11/9/92: PACE Pharmacy Provider Manual
--12/23/92: Narrow Therapeutic Index Exemption Listing
--12/92: Generic Substitution on Oral Prescriptions (Included Poster and Informational Flyers).
PACE Provider Bulletins: 1991
* 6/21/91: Co-Pay Change ($4 to $6 effective 7/1/91)
* 8/14/91: General Program Issues:
Claims Payment
Cardholder Eligibility Changes (Income Eligibility Changed to $13,000 for Single and $16,200 for Married Couples)
Nursing Home Providers
Cosmetic Drugs (Effective 10/1/91 claims for Rogaine and Retin-A no longer paid)
Paper Claims (Only claims for Compound Drugs or claims whose Quantity is in Excess of 9999 accepted as paper claims)
Persantine and Dipyridamole (These two drugs must have an indication on the prescription that it is being used as an adjunct to Coumadin anticoagulants for the prevention of postoperative thromboembolic complications of cardiac valve replacement in order to be allowed payment by (PACE).
Audit Issues (Telephone Prescriptions and Brand Medically Necessary Requirements).* 8/21/91: Final Instructions Concerning the PACE On-line Claims Adjudication System (POCAS).
* 9/27/91: Billing Instructions
* Cosmetic Drugs
* Exception Claim Processing
* POCAS, post payment review
* Nursing Home Claims
DIVISION OF CONSUMER PROTECTION
Contact: Robert Hussar, Division Chief (717)-783-6207
Current Aging Program Directives
Provided below is a comprehensive list of current Aging Program Directives. Directives which do not appear on the list are no longer in effect. Current directives are as follows:
Program Area 01--''AAA Administration''
--88-01-07 Personnel Action Plan for Private Nonprofit Area Agencies on Aging (AAA)
--91-01-01 Certification and Disclosure Regarding Lobbying
--91-01-05 Area Agency on Aging Involvement in Corporate Eldercare Activities
--92-01-01 Single Audit Act Audit Requirements
--92-01-06 Minimum Standards for Governing Boards of Private Nonprofit Area Agencies on Aging
--93-01-04 Providing AAA Funded Services to Domiciliary Care and Personal Care Home Residents
--94-01-04 Department of Aging Heat Emergency Plan
--95-01-09 Assessments of Persons With ''An Other Related Condition'' Who Are Exceptional Admissions
--97-01-02 Accounting Manual For AAA Programs
--00-01-04 PDA Waiver Paid Claims Reconciliation
--01-01-02 AAA Utilization of Federal Funds in Provision of Caregiver Services
--01-01-08 The Bridge Program
--01-01-10 Assistive Technology/ Risk Reduction Home Modification Program
--02-01-11 Updated Area Plan Assurances--Attachment A--Attachment B
--03-01-03 OPTIONS Cost Sharing--2006 Cost Share Scale
--03-01-06 Home and Community Based Services Procedures Manual (This Manual is a comprehensive guide to Department of Aging procedures. It is the operational handbook used by employees of Area Agencies on Aging. The following are individual chapters from the Manual. They contain a significant number of appendices, which are not yet displayed. They will be added to this site in the near future. In the meantime, please contact the Department at 717-783-6207 for additional information.)
* Table of Contents
* Chapter 1--Assessments
* Chapter 2--Care Management
#05-01-01, Chapter 3--APD Update (Note: New Chapter 3 listed below.)
* Chapter 3--Programs and Requirements
* Chapter 4--Services
* Chapter 5--Hearings and Appeals
--Comprehensive OPTIONS Assessment Form (COAF) Instructions
--Comprehensive OPTIONS Assessment Form
--Nursing Facility OPTIONS Assessment Form
--Functional Needs Measurement Tool Financial Resources Chart 2006
--Family Caregiver Support Program Reimbursement Benefits Chart 2006
--03-01-07 HIPAA Standards for Privacy of Individually-Identifiable Health Information and How the Requirements Impact the Pennsylvania Aging Network
--03-01-10 FY 2004-2008 Four-Year Plan Requirements
--04-01-02 AAA Program Requirements, Planning Allocations and Aging Services Block Grant Format for Fiscal Year 2004-2005
--04-01-03 AAA Program Requirements, Planning Allocations and Tobacco/Bridge Agreement Format for Fiscal Year 2004-2005
--04-01-05 FY 2004-2005 Program and Financial Reporting Requirements
--05-01-02 2004-2005 Aging Block Grant Amendment: Final Funding Allocations
--05-01-03 Area Agency on Aging (AAA) Program Requirements and Amended Planning Allocations for the Tobacco/Bridge Agreement for Fiscal Year 2004-2005
--05-01-04 Area Agency on Aging (AAA) Program Requirements, Planning Allocations and Aging Services Block Grant Format for Fiscal Year 2005-2006
--05-01-05 FY 2005-06 Data Submission Requirements Annual Submission Requirements
--05-01-06 AAA Program requirements, Plan Allocations and Reporting Requirements for the FY 2005-06 Memo to APD #05-01-06
--05-01-07 PDA Contract Procurement Requirements for Area Agencies on Aging
--05-01-08 AAA Program Requirements, Planning Allocations for the Tobacco/Bridge Agreement for the FY 2006-2006 Memo to APD #05-01-08
--05-01-09 FY 2005-2006 Annual Reporting Requirements Memo to APD #05-01-09
--05-01-10 Indirect Cost Policy for Department of Aging Contracts
--05-01-11 Area Agency on Aging Program Income Policies
--05-01-12 FY 2005-2006 Financial Reporting Requirements (FRR) Memo for APD #05-01-12
--05-01-14 Guidelines for Environmental Modifications
--06-01-01 2005-2006 Aging Block Grant Amendment Final Funding Allocation Memo to APD #06-01-01 Amendment Increase/Decrease AAA Amended Allocations for FY 2005-2006
--06-01-02 AAA Program Requirements, Final Planning Allocations and Reporting Requirements for the PDA Waiver Program Agreement for FY 2005-2006 Memo to APD #06-01-02 Schedule 1 Schedule 1
--06-01-03 PDA Waiver Program Care Plan Review Process Memo to APD #06-01-03 Care Plan Review Completion of the Care Plan Review Template Care Plan Review Spread Sheet
--06-01-04 AAA Program Requirements, Planning Allocations and Aging Services Block Grant Format for the FY 2006-2007
--06-01-05 AAA Program requirements, Final Planning Allocations for the Tobacco/Bridge Agreement for the FY 2005-2006
--06-01-06 Implementation Of Community Choice Rollout Procedures
Program Area 02--''Home Delivered Meals''
--See APD #06-03-01
Program Area 03--''Congregate Meals''
--06-03-01 Policies and Standards for the Department of Aging-Funded Nutrition Service Programs
Attachment V, Breakfast Meal Template, Five-Day Excel Version
Attachment V, Breakfast Meal Template, Seven-Day Excel Version
Attachment VI, Lunch/Dinner Meal Template, Five-Day Excel Version
Attachment VI, Lunch/Dinner meal Template, Seven-Day Excel VersionProgram Area 04--''Socialization/Recreation/Education/Health Promotion''
--96-04-01 Senior Community Center And Satellite Center Policies and Standards
--98-04-01 PrimeTime Health ProgramProgram Area 05--''Employment Services''
--96-05-02 Title V S.C.S.E.P.: Eligibility and Assessment Forms
--06-05-01 Senior Community Service Employment Program (SCSEP) Individual Employment Plan (IEP) Related Termination Guidelines
--06-05-02 Senior Community Service Employment program (SCSEP) Final Funding Allocations
--06-05-03 FY 2006-07 Title V Allocation and Slot Level and Fiscal, Program and Reporting RequirementsProgram Area 06--''Volunteer Services''
--85-06-01 Volunteer Services
Program Area 07--''Passenger Transportation Services''
--85-07-01 Policies for Transportation Services
--04-07-01 Payer of Last Resort PolicyProgram Area 09--''Legal Assistance''
--85-09-01 AAA Program of Legal Services to the Elderly
Program Area 10--''Ombudsman''
--98-10-01 Long-Term Care Ombudsman Program
--02-10-01 Implementation of Ombuds ManagerProgram Area 11--''Information and Referral''
--85-11-01 Policies and Procedures for the Provision of I & R Services by AAAs
Program Area 12--''Home Health''
--See APD #03-01-06.
Program Area 13--''Personal Care''
--See APD #03-01-06.
Program Area 14--''Personal Assistance Service''
--See APD #03-01-06.
Program Area 18--''Medical Equipment, Supplies and Adaptive Devices''
--See APD #03-01-06.
Program Area 19--''Home Support''
--See APD #03-01-06.
Program Area 20--''Adult Day Care''
--See 6 Pa. Code Chapter 11, Sections 11.1 to 11.292 and APD #03-01-06.
Program Area 22--''Assessments''
--See Chapter I of APD #03-01-06.
Program Area 23--''Care Management''
--See APD #03-01-06. (Chapter 2)
Program Area 24--''Protective Services Intake/Investigation''
--89-24-02 Required Standard Forms for Protective Services
--93-24-01 Protective Services Investigations
--93-24-02 Protective Services Investigations
--97-24-01 Protective Services Report of Need and Investigation Summary and Assessment Form
--00-24-01 Perpetrator Designation and Notification in P. S. Cases
--See APD #05-01-01Program Area 25--''Domiciliary Care''
--85-25-02 Statewide Expansion of Domiciliary Care Program
--93-25-01 Keys Amendment Implementation as It Relates to the Domiciliary Care Program
--03-25-01 Revised Domiciliary Care Agreement Forms
--05-25-01 2006 - Domiciliary Care Consumer Payment to ProvidersProgram Area 29--''Other''
--85-29-01 Changes in PSA Boundaries
--85-29-02 Generic Policies and Procedures for the Request and Consideration of Waivers of PDA Policies
--85-29-06 Interdepartmental Cooperative Agreement between the PDA and DPW, Office of Mental Health
--92-29-07 Advance Notice to Health Care Facilities Prior to Termination of Utility Service
--96-29-01 Statement of PDA Intent Re: Allocation To New Area Agencies
--97-29-01 Retention of AAA Records
--97-29-02 Emergency Operations Plan for the Department of Aging
--00-29-01 Department of Aging Energy Emergency Response Plan
--06-29-01 Memorandum of Understanding (MOU) Between Pennsylvania Department of Aging, Office of Community Services & Advocacy (OCSA) and Pennsylvania Department of Public Welfare, Office of Mental Health and Substance Abuse Services (OMHSAS)
--06-29-02 Memorandum of Understanding (MOU) Between Pennsylvania Department of Aging, Office of Community Services & Advocacy (OCSA) and Pennsylvania Department of Health, Office of Quality Assurance for the Use of the Survey Agency Information System (SAIS)
AGRICULTURE
POLICY STATEMENTS:
Bureau of Administrative Services
* Right-to-Know Procedures--Public Access to Information
Contact: Michael Mesaris (717-787-5674)
Bureau of Animal Health and Diagnostic Services
* Scrapie Containment and Eradication Strategy
Contact: Dr. Paul Knepley (717-783-8300)
* Chronic Wasting Disease Containment and Eradication Strategy
Contact: Dr. Paul Knepley (717-783-8300)
Bureau Food Distribution
* Allowable Uses of State Food Purchase Program Capital Asset Program (CAP) Monies
Contact: Sandy Hopple (717-772-2693)
Bureau of Market Development
* Guidelines: PA Agriculture Product Promotion Matching Grant Program
Contact: Pam Dailey (717-783-1450)
* Instructions for Completion of Application for Capital Improvement Matching Funds Grant
Contact: Eric Cowden (717-346-4202)
* Guidelines: Agricultural and Rural Youth Grant Program Direct and Matching Grants
Contact: Eric Cowden (717-346-4202)
Pennsylvania State Harness Racing Commission
* Licensing Procedures and Standards for Applicants
Contact: Anton J. Leppler (717-787-5196)
Pennsylvania Horse Racing Commission
* Licensing Procedures and Standards for Applicants
Contact: Benjamin H. Nolt, Jr. (717-787-1942)
Pennsylvania State Conservation Commission
* Pennsylvania's Nutrient Management Plan Implementation Grants Program Application Form and Guidelines
Contact: Karl Brown (717-787-8821)
* Pennsylvania's Nutrient Management Act Technical Manual
Contact: Karl Brown (717-787-8821)
* Nutrient Management Program Administrative Manual
Contact: Karl Brown (717-787-8821)
GUIDANCE MANUALS:
Bureau of Animal Health and Diagnostic Services
* Pennsylvania Animal Diagnostic Laboratory System User Guide
Contact: Dr. Helen Acland (717-787-8808)
Bureau of Food Distribution
* Farmers Market Nutrition Program--Farmer/Vendor Procedure Manual
* Woman, Infants and Children (''WIC'') Clinic Procedure Manual
* Self Declaration of Need: Income Poverty Guidelines for TEFAP
Contact: Sandy Hopple (717-772-2693)
Bureau of Food Safety and Laboratory Services
* rBST Labeling Information
* Application to Install or Remodel a Milking System
* Supplement to a Farm Refrigerated Bulk Milk Storage Tank and/or a Precooler Installation Application
Contact: James C. Dell (717-787-4315)
* Ice Manufacturing Plants Consumer Confidence Program Guidelines
* Reduced Oxygen Packaging (ROP) Policy and Procedures for Meat, Poultry, Fish & Seafood
* Open Air Markets Requirements for Food Protection within a Retail Food Facility
* Guidance and Requirements for Home Food Processors
* Checklist for Mobile Food Facilities in PA
* Checklist for Temporary Food Facilities Operating with Permanent Licenses in PA
* Checklist for Retail Food Facilities Operating with Temporary Licenses in PA
Contact: Lenchen Radle (717-787-4315)
Pennsylvania Harness Racing Commission
* Guidelines for Medications in Racehorses
Contact: Anton J. Leppler (717-787-5196)
Pennsylvania Horse Racing Commission
* Guidelines for Medications in Racehorses
Contact: Benjamin H. Nolt, Jr. (717-787-1942)
Bureau of Plant Industry
* Instructions for Licensing under the Pennsylvania Commercial Feed Law
* Instructions for Licensing under the Pennsylvania Fertilizer Act
* Directions for Renewing Specialty Fertilizer Registration in Pennsylvania
* Instructions for Licensing under the Pennsylvania Agricultural Liming Materials Act
Contact: John Breitsman (717-787-4843)
* Instructions for Licensing under the Pennsylvania Seed Act
Contact: Joe Garvey (717-787-5609)
* Directions for Registering Pesticides in Pennsylvania
* Experimental Pesticide Use Permits
* Grower Record Keeping Guidelines for Pesticide Applications made under an Emergency Exemption
* Instructions for Licensing under the Pennsylvania Soil and Plant Amendment Act
* Directions for Soil and Plant Amendment Registration in Pennsylvania
Contact: John Lake (717-787-4843)
* IPM for Pennsylvania Schools: A How-To Manual
Contact: Sara Pickel (717-772-5227)
* Greenhouse IPM with Emphasis on Biocontrol
Contact: Cathy Thomas (717-772-5204)
Bureau of Ride and Measurement Standards
* Amusement Ride Operators' and Attendants' Manual
Contact: Kent Shelhamer (717-787-6772)
Pennsylvania State Conservation Commission
* Best Management Practices Manual for Pennsylvania Livestock and Poultry Operations
Contact: Karl Brown (717-787-8821)
* Interim Guidance Addressing Phosphorus and other Nutrients in Nutrient Management Plans
Contact: Doug Goodlander (717-705-3895)
INTERNAL GUIDELINES:
Bureau of Farmland Preservation
* Checklist for Review of an Agricultural Conservation Easement Purchase Recommendation
* Checklist for Evaluation of a County Agricultural Conservation Easement Purchase Program
Contact: Sandra Robison (717-783-3167)
Bureau of Food Safety and Laboratory Services
* Summary of Enforcement Requirements for Violations of Bacterial Count, Somatic Cell Count and Antibiotic Residue Tests for Individual Milk Producer Samples
* Clarification of Enforcement Policy for a Producer Utilizing Two Bulk Milk Tanks
* Producer Record Transfer Program
Contact: James C. Dell (717-787-4315)
* Tolerances for Egg Quality, below which a Warning Letter shall be issued to a store
* Tolerances for Egg Quality, below which Seizure of Eggs will be made at a store
* Tolerances for Egg Quality, below which Prosecution will be initiated against a store
* Tolerances for Egg Quality, below which Seizure of Eggs will be made at a plant
Contact: Kim F. Miller (717-787-3294)
Bureau of Market Development
* Agricultural Fair Program State Premium Guideline Book
Contact: Eric Cowden (717-346-4202)
Bureau of Plant Industry
* Turfgrass Seed Certification Interagency and Interstate Certification
Contact: Joe Garvey (717-787-5609)
* Plant Pest Act Enforcement Action Penalty Matrix
Contact: Walt Blosser (717-772-5205)
* Fertilizer Enforcement Action Penalty Matrix
Contact: John Breitsman (717-787-4843)
* Soil and Plant Amendment Enforcement Action Penalty Matrix
Contact: John Breitsman (717-787-4843)
* Pesticide Enforcement Action Penalty Matrix
Contact: Joseph Uram (717-787-4843)
* Seed Enforcement Action Penalty Matrix
Contact: Joe Garvey (717-787-5609)
OTHER:
Bureau of Food Safety and Laboratory Services
* Industry Responsibilities with respect to Broken Seals
Contact: James C. Dell (717-787-4316)
* Temperature Requirements for Safe Handling of Hot and Cold Foods
* Guidelines for Self-Service Bulk Food Displays
* Guidelines for Maple Syrup Operations
Contact: Lenchen Radle (717-787-4315)
* A Retailer's Guide to Assuring Shelf Egg Safety & Quality
* Safe Handling of Eggs
* Safe Handling of Fresh Fruits & Vegetables
Contact: Kim F. Miller (717-787-3294)
Bureau of Plant Industry
* Pennsylvania Pesticide Hypersensitivity Registration Information
Contact: Dave Scott (717-772-5214)
[Continued on next Web Page]
No part of the information on this site may be reproduced for profit or sold for profit.This material has been drawn directly from the official Pennsylvania Bulletin full text database. Due to the limitations of HTML or differences in display capabilities of different browsers, this version may differ slightly from the official printed version.
